GLP-1 Coverage Debate Comes Down to a ‘Prisoner's Dilemma,’ Lilly SVP Says
Summary
Employers are debating whether to cover GLP-1 therapies, medicines that help treat obesity and related health issues. While these drugs can be expensive, experts say not covering them may lead to higher health problems and costs in the future. Employers face challenges because benefits from these treatments may take years to appear, and workers often change jobs before then.Key Facts
- GLP-1 therapies are medicines used to manage obesity and type 2 diabetes.
- About 100 million U.S. adults have obesity, contributing to over $261 billion in health costs yearly.
- Only 36% of employers currently offer coverage for GLP-1 treatments for both diabetes and weight loss.
- Employers find it hard to invest in obesity treatments because financial benefits may take years to show.
- Average U.S. employee stay at a job is 3.9 years, but some drug benefits may take up to 12 months to appear.
- Some employers delay paying for these treatments, hoping others will cover costs first.
- Making GLP-1 coverage part of long-term employee benefits could help retain workers.
- Offering GLP-1 coverage may attract new employees in a competitive job market.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.